How is the Trump administration tightening Medicare drug price negotiation rules?

The Trump administration has proposed a policy change to close a loophole in Medicare’s drug price negotiation framework. The effort seeks to make negotiated price provisions more consistent across covered products, potentially expanding the range of drugs subject to negotiation and increasing compliance demands for manufacturers.